Company
Scholar Rock
Nasdaq: SRRK
Cambridge, Massachusetts biotech developing growth-factor antibodies, led by apitegromab for spinal muscular atrophy.
1 story
Regulatory News has published 1 story about Scholar Rock on 18 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 18 September 2026.
This page is generated from Regulatory News’ editorial coverage of Scholar Rock. It is not an advertisement.
On the record
- Company
- Scholar Rock Holding Corporation (Nasdaq: SRRK)
- Headquarters
- Cambridge, Massachusetts
- Regulator
- U.S. Food and Drug Administration (CDER)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
